The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Inhibace     (5S,8S)-5-[[(1S)-1- ethoxycarbonyl-3-phenyl...

Synonyms: Cilazil, Inibace, Vascace, Dynorm, Justor, ...
This record was replaced with 56330.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cilazapril


High impact information on cilazapril


Chemical compound and disease context of cilazapril


Biological context of cilazapril


Anatomical context of cilazapril

  • To assess the influence of cilazapril on myofibrotic changes after balloon injury, control (n = 7) or cilazapril-treated (n = 9) (20 mg/kg b.i.d.) normal 3-month-old pigs underwent dilatation angioplasty of the right, and deendothelialization of the left common carotid artery [9].
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) [19].
  • The significant thickening of the basement membrane observed in the diabetic normotensive (132.8+/-19.4 nm) and diabetic hypertensive (150.3+/-20.2 nm) groups was decreased by cilazapril in the diabetic hypertensive group (116.7+/-11.0 nm, p<0.01), but was unaffected in the normotensive (131.9+/-17.3 nm) group [20].
  • Candesartan and cilazapril equally prevented increases in hypertrophy in noninfarcted myocardium, left ventricular dilatation, and ejection fraction at 4 weeks [21].
  • Brachial artery acetylcholine infusions increased forearm blood flow from 2.95 +/- 1.5 to a maximum of 22.8 +/- 11.5 ml.min-1.100 ml-1 forearm tissue and decreased forearm vascular resistance from 48.1 +/- 34.1 to 6.9 +/- 6.9 units before cilazapril [22].

Associations of cilazapril with other chemical compounds


Gene context of cilazapril


Analytical, diagnostic and therapeutic context of cilazapril


  1. Subacute cutaneous lupus erythematosus associated with cilazapril. Fernández-Díaz, M.L., Herranz, P., Suárez-Marrero, M.C., Borbujo, J., Manzano, R., Casado, M. Lancet (1995) [Pubmed]
  2. Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action. Dietz, R., Waas, W., Süsselbeck, T., Willenbrock, R., Osterziel, K.J. Circulation (1993) [Pubmed]
  3. Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in rats. Clozel, J.P., Müller, R.K., Roux, S., Fischli, W., Baumgartner, H.R. Circulation (1993) [Pubmed]
  4. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. Mulder, P., Richard, V., Compagnon, P., Henry, J.P., Lallemand, F., Clozel, J.P., Koen, R., Macé, B., Thuillez, C. J. Am. Coll. Cardiol. (1997) [Pubmed]
  5. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Imanishi, M., Yoshioka, K., Konishi, Y., Okumura, M., Okada, N., Sato, T., Tanaka, S., Fujii, S., Kimura, G. Diabetologia (1999) [Pubmed]
  6. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Powell, J.S., Clozel, J.P., Müller, R.K., Kuhn, H., Hefti, F., Hosang, M., Baumgartner, H.R. Science (1989) [Pubmed]
  7. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Kim, S., Izumi, Y., Yano, M., Hamaguchi, A., Miura, K., Yamanaka, S., Miyazaki, H., Iwao, H. Circulation (1998) [Pubmed]
  8. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Sventek, P., Turgeon, A., Schiffrin, E.L. Circulation (1997) [Pubmed]
  9. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Lam, J.Y., Lacoste, L., Bourassa, M.G. Circulation (1992) [Pubmed]
  10. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. Powell, J.S., Muller, R.K., Baumgartner, H.R. J. Am. Coll. Cardiol. (1991) [Pubmed]
  11. Efficacy of cilazapril compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. Multicentre Study Group. Morgan, T.O. Am. J. Med. (1989) [Pubmed]
  12. Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Clozel, J.P., Véniant, M., Hess, P., Sprecher, U. Hypertension (1991) [Pubmed]
  13. Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. Fletcher, A.E., Bulpitt, C.J., Chase, D.M., Collins, W.C., Furberg, C.D., Goggin, T.K., Hewett, A.J., Neiss, A.M. Hypertension (1992) [Pubmed]
  14. Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hajdu, M.A., Heistad, D.D., Baumbach, G.L. Hypertension (1991) [Pubmed]
  15. Coronary blood flow in renovascular hypertension. Magrini, F., Reggiani, P., Fratianni, G., Morganti, A., Zanchetti, A. Am. J. Med. (1993) [Pubmed]
  16. Antihypertensive efficacy of cilazapril in general practice: assessment by ambulatory blood pressure monitoring. Waeber, B., Wohler, D., Lüscher, T.F., Schubiger, J.L., Brunner, H.R. Am. J. Med. (1993) [Pubmed]
  17. Clinical pharmacology of cilazapril. Kleinbloesem, C.H., Van Brummelen, P., Francis, R.J., Wiegand, U.W. Am. J. Med. (1989) [Pubmed]
  18. A single dose of cilazapril improves diastolic function in hypertensive patients. Marmor, A., Green, T., Krakuer, J., Szucs, T., Schneeweiss, A. Am. J. Med. (1989) [Pubmed]
  19. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). Berger, P.B., Holmes, D.R., Ohman, E.M., O'Hanesian, M.A., Murphy, J.G., Schwartz, R.S., Serruys, P.W., Faxon, D.P. J. Am. Coll. Cardiol. (1996) [Pubmed]
  20. Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: protective effects of ACE inhibition. Dosso, A.A., Rungger-Brändle, E., Leuenberger, P.M. Diabetologia (2004) [Pubmed]
  21. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Yoshiyama, M., Takeuchi, K., Omura, T., Kim, S., Yamagishi, H., Toda, I., Teragaki, M., Akioka, K., Iwao, H., Yoshikawa, J. Hypertension (1999) [Pubmed]
  22. Effects of angiotensin converting enzyme inhibition on endothelial vasodilator function in primary human hypertension. Kiowski, W., Linder, L., Nuesch, R., Martina, B. Eur. Heart J. (1993) [Pubmed]
  23. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Velussi, M., Brocco, E., Frigato, F., Zolli, M., Muollo, B., Maioli, M., Carraro, A., Tonolo, G., Fresu, P., Cernigoi, A.M., Fioretto, P., Nosadini, R. Diabetes (1996) [Pubmed]
  24. Some metabolic aspects of essential hypertension and its treatment. Santoro, D., Galvan, A.Q., Natali, A., Ferrannini, E. Am. J. Med. (1993) [Pubmed]
  25. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Schiffrin, E.L., Turgeon, A., Deng, L.Y. Br. J. Pharmacol. (1997) [Pubmed]
  26. Altered expression of Na(+)/H(+) exchanger isoforms 1 and 3 in clipped and unclipped kidneys of a 2-kidney-1-clip Goldblatt model of hypertension. Khan, I., Al-Qattan, K.K., Alnaqeeb, M.A., Ali, M. Nephron (2002) [Pubmed]
  27. Ro 42-5892 is a potent orally active renin inhibitor in primates. Fischli, W., Clozel, J.P., el Amrani, K., Wostl, W., Neidhart, W., Stadler, H., Branca, Q. Hypertension (1991) [Pubmed]
  28. Effect of renin-angiotensin inhibition on glomerular injuries in DOCA-salt hypertensive rats. Oishi, T., Ogura, T., Yamauchi, T., Harada, K., Ota, Z. Regul. Pept. (1996) [Pubmed]
  29. Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. Holck, M., Fischli, W., Hefti, F., Gerold, M. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  30. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. Drexler, H., Banhardt, U., Meinertz, T., Wollschläger, H., Lehmann, M., Just, H. Circulation (1989) [Pubmed]
  31. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Rakugi, H., Wang, D.S., Dzau, V.J., Pratt, R.E. Circulation (1994) [Pubmed]
  32. Efficacy and safety of cilazapril in elderly patients with essential hypertension. A multicenter study. Kobrin, I., Ben-Ishay, D., Bompani, R., Dixon, R., Hoverman, R.J., Jones, R.W., Kögler, P., Sanchez, R. Am. J. Med. (1989) [Pubmed]
  33. Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension. Kögler, P. Am. J. Med. (1989) [Pubmed]
WikiGenes - Universities